Multicenter Study on Costs Associated with Two Surgical Procedures: GreenLight XPS 180 W Versus the Gold Standard Transurethral Resection of the Prostate.

Objective: To analyze the costs associated with two surgical procedures for lower urinary tract symptoms secondary to benign prostatic hyperplasia: GreenLight XPS 180 broken vertical bar W versus the gold standard transurethral resection of the prostate.Methods: A multicenter, retrospective cost study was carried out from the National Health Service perspective, over a 3-month time period. Costs were broken down into pre-surgical, surgical and post-surgical phases. Data were extracted from records of patients operated sequentially, with IPSS = 15, Qmax = 15 mL/seg and a prostate volume of 40-80 mL, adding only direct healthcare costs (, is an element of 2013) associated with the procedure and management of complications.Results: A total of 79 patients sequentially underwent GL XPS (n: 39) or TURP (n: 40) between July and October, 2013. Clinical outcomes were similar (94.9% and 92.5%, GL XPS and TURP, respectively) without significant differences (P = .67). The average direct cost per patient was reduced by is an element of 114 in GL XPS versus TURP patients; the cost was higher in the surgical phase with GL XPS (difference: is an element of 1,209; P < .001) but was lower in the post-surgical phase (difference: is an element of-1,351; P < .001).Conclusions: The GreenLight XPS 180-W laser system is associated with a reduction in costs with respect to transurethral resection of prostate in the surgical treatment of LUTS secondary to PBH. This reduction is due to a shorter inpatient length of stay that offsets the cost of the new technology. (C) 2013 AEU. Published by Elsevier Espana, S.L. All rights reserved.